XENEXenon Pharmaceuticals Inc.
$36.44-1.4% 1Y
$36.44
$36.1752 weeks$68.91
The financials
Xenon Pharmaceuticals Inc. by the numbers
Xenon Pharmaceuticals Inc. (XENE) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $111M. For the full year FY2025, revenue was $7.5M and net income −$346M. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | n/a |
| Operating income | −$123M | −$94M | n/a |
| Net income | −$111M | −$85M | n/a |
| Diluted EPS | −$1.11 | −$1.07 | n/a |